Upfront therapy: the case for continuous treatment

Constantine S. Tam

doi:10.1182/hematology.2021000232

Upfront therapy: the case for continuous treatment

Constantine S. Tam

Research output: Contribution to journal › Article › Other › peer-review

1 Citation (Scopus)

Abstract

Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.

Original language	English
Pages (from-to)	55-58
Number of pages	4
Journal	Hematology
Volume	2021
Issue number	1
DOIs	https://doi.org/10.1182/hematology.2021000232
Publication status	Published - 10 Dec 2021
Externally published	Yes

Access to Document

10.1182/hematology.2021000232

Cite this

@article{037f95845a0442e0bd30d970f0541130,

title = "Upfront therapy: the case for continuous treatment",

abstract = "Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.",

author = "Tam, {Constantine S.}",

note = "Funding Information: Constantine S. Tam: Research funding from Janssen, AbbVie, and Beigene; honoraria from Janssen, Pharmacyclics, Beigene, and AbbVie. Publisher Copyright: {\textcopyright} 2021 by The American Society of Hematology",

year = "2021",

month = dec,

day = "10",

doi = "10.1182/hematology.2021000232",

language = "English",

volume = "2021",

pages = "55--58",

journal = "Hematology",

issn = "1520-4391",

publisher = "American Society of Hematology",

number = "1",

}

TY - JOUR

T1 - Upfront therapy

T2 - the case for continuous treatment

AU - Tam, Constantine S.

N1 - Funding Information: Constantine S. Tam: Research funding from Janssen, AbbVie, and Beigene; honoraria from Janssen, Pharmacyclics, Beigene, and AbbVie. Publisher Copyright: © 2021 by The American Society of Hematology

PY - 2021/12/10

Y1 - 2021/12/10

N2 - Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.

AB - Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.

UR - http://www.scopus.com/inward/record.url?scp=85122433592&partnerID=8YFLogxK

U2 - 10.1182/hematology.2021000232

DO - 10.1182/hematology.2021000232

M3 - Article

C2 - 34889433

AN - SCOPUS:85122433592

SN - 1520-4391

VL - 2021

SP - 55

EP - 58

JO - Hematology

JF - Hematology

IS - 1

ER -

Upfront therapy: the case for continuous treatment

Abstract

Access to Document

Other files and links

Cite this